Analytical Services in Discovery, Early Development & Development


NON-GLP OR GLP

Type of Service

Endpoints

Method development / validation

Method development /analysis for screening PK

 

GLP-method development

 

Stability in formulations

 

Stability in plasma/serum

Analysis

Bioanalysis GLP or non-GLP

 

Metabolite screens (12C or 14C)

 

Radio-analysis (preclinical or clinical)

 

Metabolite ID

 

PK regulatory (single or repeated dose)

* 3rd party supplier

 

Contact

Business Development
Please send us an Email!

 

 

Dr. Michael Gassen
Managing Director 
Nuvisan Pharma Grafing GmbH

Dr. Sylvie Bruchmann
Vice President